U01 Research Project Cooperative Agreement
Accelerating Medicines Partnership (AMP) in Type 2 Diabetes (U01)
This Funding Opportunity Announcement (FOA) invites applications for the Accelerating Medicines Partnership (AMP) in Type 2 Diabetes (T2D-GENES) consortium. The AMP T2D-GENES will build on and expand the previous work of the T2D GENES consortium. The aim of the consortium is to characterize the genetic variations in human genomic regions that have been putatively associated with type 2 diabetes (T2D) and conduct follow-up functional studies of particular genetic variants. The data coordinating center for the consortium is being solicited via the companion FOA.
|Notice(s) for this Opportunity|
|Letter of Intent Due Date|
June 18, 2014
|Application Due Date|
July 18, 2014, by 5:00 PM local time of applicant organization.